MA48944B1 - Forme cristalline de n-butyldéoxygalactonojirimycine - Google Patents

Forme cristalline de n-butyldéoxygalactonojirimycine

Info

Publication number
MA48944B1
MA48944B1 MA48944A MA48944A MA48944B1 MA 48944 B1 MA48944 B1 MA 48944B1 MA 48944 A MA48944 A MA 48944A MA 48944 A MA48944 A MA 48944A MA 48944 B1 MA48944 B1 MA 48944B1
Authority
MA
Morocco
Prior art keywords
crystalline form
butyldeoxygalactonojirimycin
triol
piperidine
hydroxymethyl
Prior art date
Application number
MA48944A
Other languages
English (en)
Other versions
MA48944A (fr
Inventor
Vitor Oliveira
Ivan POGORELIC
Jean-Paul Roduit
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of MA48944A publication Critical patent/MA48944A/fr
Publication of MA48944B1 publication Critical patent/MA48944B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

L'invention concerne une forme cristalline de [(2R,3S,4R,5S)-1-butyl-2-(hydroxyméthyl)-pipéridine-3,4,5-triol, des procédés pour sa préparation, des compositions pharmaceutiques contenant une telle forme cristalline, et son utilisation en tant que médicament, en particulier en tant qu'inhibiteur de la biosynthèse de glycolipides.
MA48944A 2017-06-01 2018-05-31 Forme cristalline de n-butyldéoxygalactonojirimycine MA48944B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2017063287 2017-06-01
EP18728624.0A EP3630725B1 (fr) 2017-06-01 2018-05-31 Forme cristalline de n-butyldéoxygalactonojirimycine
PCT/EP2018/064365 WO2018220131A1 (fr) 2017-06-01 2018-05-31 Forme cristalline de n-butyldéoxygalactonojirimycine

Publications (2)

Publication Number Publication Date
MA48944A MA48944A (fr) 2020-04-08
MA48944B1 true MA48944B1 (fr) 2025-12-31

Family

ID=62492649

Family Applications (1)

Application Number Title Priority Date Filing Date
MA48944A MA48944B1 (fr) 2017-06-01 2018-05-31 Forme cristalline de n-butyldéoxygalactonojirimycine

Country Status (27)

Country Link
US (2) US11306058B2 (fr)
EP (1) EP3630725B1 (fr)
JP (2) JP6937850B2 (fr)
KR (1) KR102612650B1 (fr)
CN (1) CN110799497A (fr)
AU (1) AU2018278247B2 (fr)
CA (1) CA3065147A1 (fr)
CL (1) CL2019003478A1 (fr)
DK (1) DK3630725T3 (fr)
EA (1) EA201992807A1 (fr)
ES (1) ES3059191T3 (fr)
FI (1) FI3630725T3 (fr)
HR (1) HRP20251697T1 (fr)
IL (1) IL270961B2 (fr)
LT (1) LT3630725T (fr)
MA (1) MA48944B1 (fr)
MX (1) MX2019014427A (fr)
MY (1) MY201196A (fr)
NZ (1) NZ760100A (fr)
PH (1) PH12019502635A1 (fr)
PL (1) PL3630725T3 (fr)
PT (1) PT3630725T (fr)
RS (1) RS67675B1 (fr)
SI (1) SI3630725T1 (fr)
TW (1) TWI770184B (fr)
UA (1) UA125938C2 (fr)
WO (1) WO2018220131A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018278247B2 (en) * 2017-06-01 2022-07-28 Idorsia Pharmaceuticals Ltd Crystalline form of N-butyldeoxygalactonojirimycin
EP4034256B1 (fr) 2019-09-25 2025-11-19 Assia Chemical Industries Ltd. Formes à l'état solide de sels de lucérastat et leur procédé de préparation
WO2025017212A1 (fr) 2023-07-20 2025-01-23 Katholieke Universiteit Leuven Inhibiteurs de synthase de glucosyltransférase de céramide d'udp-glucose (ugcg) dans le traitement du cancer
TR2024011149A1 (tr) * 2024-08-23 2026-03-23 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Mi̇galastat i̇çeren kapsül formülasyonlari

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2086413A1 (fr) * 1990-06-29 1991-12-30 Yohji Ezure Derives piperidine
US6291657B1 (en) * 1993-05-13 2001-09-18 Monsanto Company Deoxygalactonojirimycin derivatives
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
GB0100889D0 (en) 2001-01-12 2001-02-21 Oxford Glycosciences Uk Ltd Compounds
GB0229476D0 (en) * 2002-12-17 2003-01-22 Oxford Glycosciences Uk Ltd Novel process
FR2861991B1 (fr) * 2003-11-07 2008-01-18 Centre Nat Rech Scient Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
US7884115B2 (en) 2004-09-28 2011-02-08 Allergan, Inc. Methods and compositions for the treatment of pain and other neurological conditions
EP2932982B1 (fr) 2005-05-17 2018-10-03 Amicus Therapeutics, Inc. Procédé pour le traitement de la maladie de Pompe au moyen de 1-désoxynojirimycine et de ses dérivés
AU2006272497B2 (en) 2005-07-27 2012-07-19 University Of Florida Research Foundation, Inc. Small compounds that correct protein misfolding and uses thereof
AU2007241622A1 (en) 2006-04-24 2007-11-01 Academisch Medisch Centrum Improved treatment of cystic fibrosis
GB0712494D0 (en) 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
ITMI20122090A1 (it) * 2012-12-06 2014-06-07 Dipharma Francis Srl Sintesi di un inibitore delle glicosiltransferasi
AU2018278247B2 (en) 2017-06-01 2022-07-28 Idorsia Pharmaceuticals Ltd Crystalline form of N-butyldeoxygalactonojirimycin

Also Published As

Publication number Publication date
IL270961A (en) 2020-01-30
TWI770184B (zh) 2022-07-11
MY201196A (en) 2024-02-09
WO2018220131A1 (fr) 2018-12-06
JP2020521796A (ja) 2020-07-27
JP7373529B2 (ja) 2023-11-02
IL270961B1 (en) 2024-11-01
UA125938C2 (uk) 2022-07-13
JP2021185184A (ja) 2021-12-09
US11713297B2 (en) 2023-08-01
MX2019014427A (es) 2020-02-05
US11306058B2 (en) 2022-04-19
AU2018278247A1 (en) 2020-01-16
CA3065147A1 (fr) 2018-12-06
US20220002245A1 (en) 2022-01-06
EP3630725A1 (fr) 2020-04-08
EP3630725B1 (fr) 2025-10-29
EA201992807A1 (ru) 2020-05-20
RS67675B1 (sr) 2026-02-27
CN110799497A (zh) 2020-02-14
PH12019502635A1 (en) 2020-07-13
HRP20251697T1 (hr) 2026-02-27
FI3630725T3 (fi) 2026-01-27
US20200140385A1 (en) 2020-05-07
MA48944A (fr) 2020-04-08
BR112019025125A2 (pt) 2020-07-21
NZ760100A (en) 2026-03-27
TW201902876A (zh) 2019-01-16
IL270961B2 (en) 2025-03-01
JP6937850B2 (ja) 2021-09-22
DK3630725T3 (da) 2026-02-09
LT3630725T (lt) 2026-01-12
ES3059191T3 (en) 2026-03-19
SI3630725T1 (sl) 2026-01-30
KR20200011992A (ko) 2020-02-04
PT3630725T (pt) 2026-01-27
CL2019003478A1 (es) 2020-06-05
PL3630725T3 (pl) 2026-03-23
KR102612650B1 (ko) 2023-12-11
AU2018278247B2 (en) 2022-07-28

Similar Documents

Publication Publication Date Title
MA48944B1 (fr) Forme cristalline de n-butyldéoxygalactonojirimycine
MA44851A (fr) Dérivés pyridinyltriazole substitués par des groupements amides et leurs utilisations
PE20081736A1 (es) Compuestos triciclicos, composiciones, y procedimientos
MA33679B1 (fr) Derives de 2-oxo-1-pyrrolidinyle imidazothiadiazole
MA30762B1 (fr) Anticorps specifiques du prlr et leurs utilisations
MA32471B1 (fr) Composés de borates esters et compositions pharmaceutiques contenant des composés
MA30807B1 (fr) Compositions pharmaceutiques.
EA201990831A1 (ru) Смесительная система для получения косметического продукта и косметическая капсула
MA42946B1 (fr) Sels et formes solides d'un antibiotique de type monobactame
MA29264B1 (fr) Pyroles et imidazoles substitues, compositions les contenant, procede de fabrication et utilisation
PH12019502562B1 (en) N-substituted indole derivatives
MA37666B1 (fr) Sel de camsylate
MA29278B1 (fr) Composition pharmaceutique comprenant un derive de l'indolylmaleimide
AR059927A1 (es) Metodos para la estabilizacion de composiciones inestables a la oxidacion y composiciones oftalmicas estabilizadas
MA40366A (fr) Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines
WO2020221916A3 (fr) Composition eutectique
MA44079B1 (fr) Compositions pharmaceutiques comprenant un dérivé de phénylaminopyrimidine
PH12017501397A1 (en) (2s, 4r)-5-(5`-chloro-2`-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor
MA38679A1 (fr) Modulateurs du récepteur de cxcr7
WO2018193090A3 (fr) Procédé de préparation d'hémitartrate d'eliglustat et d'intermédiaires de celui-ci
MA44965A (fr) Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3
MA41174B1 (fr) Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines
MA46266B1 (fr) Formes cristallines
MA34580B1 (fr) Valsartan hautement cristallin